RxDoctor Payments DataLook up a doctor →

Akil Loli, MD

Interventional Cardiology · Phoenix, AZNPI 1962453803

Payments from drug & device makers

$505,935in general payments, 2019–2025

Across 971 payments — averaging $521.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$221K
  • Cvrx, Inc.$66K
  • Abbott$58K
  • Abiomed$40K
  • Shockwave Medical, Inc$37K
  • Boston Scientific$34K
  • plus $50K from 35 others

What the payments were for

  • Consulting fees$30,75019%
  • Speaking & faculty fees$68,32543%
  • Travel & lodging$21,99914%
  • Food & beverage$38,53124%
  • Education$2150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$505,935 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$731,189
Medicare patients
1,198
Services billed
5,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$140,440
EntrestoSacubitril/Valsartan71$110,218
XareltoRivaroxaban47$66,392
Repatha SureclickEvolocumab72$65,801
OzempicSemaglutide28$38,863
Praluent PenAlirocumab33$30,694
BrilintaTicagrelor35$29,256
FarxigaDapagliflozin Propanediol15$16,223
Repatha SyringeEvolocumab12$6,503
Ranolazine ErRanolazine34$4,037
ClopidogrelClopidogrel Bisulfate344$3,892
Losartan Potassium304$3,022
Atorvastatin Calcium309$2,371
Isosorbide Dinitrate44$2,351
Rosuvastatin Calcium215$2,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$140,440106 claims
NovartisEntresto$14$110,21871 claims
Johnson & JohnsonXarelto$79$66,39247 claims
AstraZenecaBrilinta, Farxiga$250$45,47950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →